• Welcome to Meilleur Technologies

Meilleur Technologies Inc.

We will revolutionize the use of molecular imaging of neurodegenerative disease to accelerate the development of effective therapies to treat Alzheimer’s Disease and other cognitive disorders

About Us

Meilleur Technologies mission is to be the premier provider of biomarkers and associated information management tools. We are committed to work in close alignment with other stakeholders in brain health: pharma, academia, the clinical community and non-profit organizations. We are focused on building on our existing collaborations with pharma development and academic thought leader partners.  We expect that our efforts will result in significant acceleration of improved treatments for neurodegenerative diseases.

Contact Us

Development and Use of Biomarkers are Essential Elements In Accelerating Development Of Disease Modifying Therapies (DMTs), Especially In Alzheimer’s Disease (AD)

Biomarkers have become critical proof standards in clinical studies supporting the development of DMTs. With the advent of Positron Emission Tomography (PET) imaging biomarkers, the ability to visually detect β-amyloid plaques and tau tangles has greatly enhanced the ability of researchers and clinicians to identify the presence of these pathologies. This new and growing capability is rapidly increasing the accuracy and confidence in clinical diagnoses for AD, which previously was only accomplished by post-mortem histopathology

 

 

 

 

Alzheimer’s Disease Prevalence And ß-Amyloid Plaques

    • AD is the sixth leading cause of death in the United States.
    • Approximately 5.8 million US residents are living with the disease today; that number is projected to rise to nearly 14 million by the year 2050.
    • In 2019, AD and other dementias will cost the US $290 billion and this amount is projected to rise to $1.1 trillion by 2050.
    • Several promising candidates are in late stage development along with a rich pipeline of early stage targets. The initial wave of candidates, focused on BACE (β-amyloid precursor protein cleaving enzyme) inhibitors, has now given way to new approaches, most notably antibodies targeting aggregated forms of tau.
    • β-amyloid imaging agents are now commonly used as biomarkers in AD clinical trials, largely to enrich enrollment.

 

 

 




Meilleur’s late stage biomarker, NAV-4694, ipoised to provide pharma and academic researchers with a ‘best in class’ second generation ß-Amyloidimaging biomarker